– Expanded benchmarking of IMM-1-104 as a single agent across more than 190 patient-aligned models in humanized 3D-tumor growth assays demonstrated high sensitivity in a wide range of MAPK-driven ...
The abstracts will be available on the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics website. Following presentation, the posters will be available on the ...
CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for ...
Immuneering (IMRX) will hold a virtual Investor Event in early January 2025 to discuss data from its ongoing Phase 2a trial of IMM-1-104. Specifically, the company plans to present: Additional data ...
Immuneering Corp. has obtained FDA clearance of its IND application for IMM-6-415, an oral, twice-daily small molecule in development for the treatment of advanced RAF or RAS mutant solid tumors.
As of December 5, 2024, three patients achieved complete or partial responses for an overall response rate of 43% (3/7) and a disease control rate of 86% (6/7). Four patients remain on treatment. The ...
-Dose evaluation portion of IMM-1-104 Phase 1/2a trial approximately two-thirds enrolled; Immuneering’s recommendation for a Phase 2 dose expected in early 2024 - - Expanded clinical development plan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results